Oncology Drugs Market Is Expected to Grow at A CAGR of 12.7% Over the Forecast Period Owing to Rising Number of Pipeline Cell-Therapy Products, Says Absolute Markets Insights

Oncology Drugs Market is Rapidly Growing with Top Key Players F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company

News provided by

Absolute Markets Insights

Sep 10, 2019, 09:41 ET

PUNE, India, Sept. 10, 2019 /PRNewswire/ -- In the recent past, the FDA approved cell therapies to treat CD19-positive hematological cancers. This have in turn encouraged research institutes to indulge themselves in substantial Research & Development to innovate more number of cell therapies associated with Cancer. Such a factor is expected to aid the global oncology drugs market over the forecast period. However, side-effects associated with these drugs has critically impacted the global industry growth in recent years. The global cancer cell therapy pipeline includes 1,011 active agents. Amongst them, the chimeric antigen receptor (CAR)-T cell therapy number has increased substantially and is cumulating to a total of 568 agents. Such a trend is expected to propel the overall oncology drug market growth in future years.

Request for Sample Copy@

https://www.absolutemarketsinsights.com/request_sample.php?id=273

The detailed research study provides qualitative and quantitative analysis of the global oncology drugs market. The market has been analyzed from demand as well as supply side. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Key Findings of the Report:

In terms of revenue, global oncology drugs market was valued at US$ 119 billion in 2018. The introduction and approval of anti-PD-1 agents' nivolumab and pembrolizumab for NSCLC has bought a new era for the cancer industry.
The number of patients receiving single-agent chemotherapy decreased considerably in the recent past and the patients who received EGFR-TKI based therapy also reduced substantially
Single drug therapies coupled with monoclonal antibodies against programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little efficacy in patients suffering from metastatic breast cancer. The same is low number of tumour-infiltrating lymphocytes, found in most of the breast cancers. As a result, the development of combinations of molecularly targeted therapies and immunotherapy have proven to be a great success.
The China and United States hold the leading positions in the cancer cell therapy pipeline. The number for the same are 439 and 305 agents respectively. Majority of the drugs developed in the United States are at pre-clinical stage, whereas the drugs that are being developed in China are at clinical stages
Some of the industry participants present in the oncology drugs market are F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca, Merck & Co., Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals amongst others
In August, 2019, the U.S. FDA granted approval to Rozlytrek. This drug is for adoslescents and adult who are suffering from genetic cancer defects. This drug got approval for treating diseases like NTRK (neurotrophic tyrosine receptor kinase) gene fusion. The drug has a unique ability to shrink tumors and has been evaluated in four clinical trials, studying the adults who are suffering from NTRK fusion-positive tumors.

Enquiry Before Buying@

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=273

Oncology drugs market By Indication

Breast Cancer
Prostate Cancer
Basal Cell Cancer
Skin Cancer (Non-Melanoma)
Colorectal cancer
Lung Cancer
Renal Cancer
Bladder Cancer
Lymphoma
Others

Oncology drugs market By Treatment

Drug Therapies

Antimetabolites
Antitumor Antibiotics
Asparagine-Specific Enzymes
Bisphosphonates & Biosimilars
DNA-Damaging Agents (Antineoplastics) and Alkylating Agents
Inhibitors

DNA-Repair Enzyme Inhibitors
Histone Deacetylase Inhibitors
Janus-Associated Kinase (JAK) Inhibitors
Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
Proteasome Inhibitors
Tyrosine Kinase Inhibitors
PD-1 and PD-L1 inhibitorsOthers

Monoclonal Antibodies
Others

Surgery

Open Surgery
Minimally Invasive Surgery

Radiation Therapy
Chemotherapy
Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy
Cytokine Treatment
Donor lymphocyte infusion
Monoclonal Antibody Treatment
Others

Targeted Therapy
Hormone Therapy
Stem Cell Transplant

Autologous stem cell transplantation
Allogeneic stem cell transplantation
Reduced-Intensity Allogeneic Stem Cell Transplantation
Graft-Versus-Host Disease

Precision Medicine
Others

By Geography

North America

U.S.
Canada
Mexico
Rest of North America

Europe

France
The UK
Spain
Germany
Italy

Nordic Countries

Denmark
Finland
Iceland
Norway
Sweden

Benelux Union

Belgium
The Netherlands
Luxemburg

Rest of Europe

Asia Pacific

China
Japan
India
New Zealand
Australia
South Korea
Southeast Asia

Indonesia
Thailand
Malaysia
Singapore
Rest of Southeast Asia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of Middle East & Africa

Latin America

Brazil
Argentina
Rest of Latin America

Purchase the Premium Report@

https://www.absolutemarketsinsights.com/checkout?id=273

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,
Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/

Follow Us on Social Media:

https://www.facebook.com/AbsoluteMarketsInsights/

https://twitter.com/AbsoluteMI

https://www.linkedin.com/company/absolute-markets-insights/

https://plus.google.com/117657938830005040584

SOURCE Absolute Markets Insights